Welcome to our store

News

Semaglutide Muscle Loss Regulatory Response: 20...

June 12, 2026

The FDA and EMA approved the first semaglutide-MOTS-c combination therapies in early 2025, responding to evidence that GLP-1 agonists accelerate muscle loss during weight reduction.

Semaglutide Muscle Loss Regulatory Response: 20...

June 12, 2026

The FDA and EMA approved the first semaglutide-MOTS-c combination therapies in early 2025, responding to evidence that GLP-1 agonists accelerate muscle loss during weight reduction.

Clarington Peptides (PC)

High-quality peptides designed for consistency, purity, and trusted research performance.

QUICK LINKS

OUR POLICIES

CONTACT

info@sainte-foypeptides.ca

70 Temperance St, Toronto, ON, M5H 0B1

⚠ Research Use Only — Legal Disclaimer

All products are sold for research purposes only. Not intended for human or animal use. Not approved by Health Canada or the FDA. By purchasing, you confirm eligibility as a qualified researcher and accept full liability for use. We disclaim all responsibility for adverse outcomes resulting from misuse.